Startseite Kongressberichte & Archiv 24th Congress of EHA Novel agents for newly diagnosed plasma cell dyscrasias

Novel agents for newly diagnosed plasma cell dyscrasias

Maria-Victoria Mateos, Joaquín Martínez-López, Paula Rodríguez-Otero, Verónica González de la Calle, et al.

CURATIVE STRATEGY (GEM-CESAR) FOR HIGH-RISK SMOLDERING MYELOMA: CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (KRD) AS INDUCTION FOLLOWED BY HDT-ASCT, CONSOLIDATION WITH KRD AND MAINTENANCE WITH RD

Conclusion:  The primary end point of the trial was met, and 56% of the pts who completed induction and HDT-ASCT achieved MRD-ve. This “curative strategy for high risk SMM” continues being encouraging and 93% of pts remain alive and progression-free at 30 months and 98% of pts alive.  

 

Francesca Gay, Chiara Cerrato, Delia Rota Scalabrini, Angelo Belotti, et al.

CARFILZOMIB LENALIDOMIDE DEXAMETHASONE (KRD) WITH OR WITHOUT TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA (FORTE TRIAL): EFFICACY ACCORDING TO RISK STATUS

Conclusion: KRd-ASCT-KRd and KRd12 were equally effective in inducing high-quality responses, and approximately 50% of high-risk patients achieved MRD negativity. In addition, ASCT proved to be beneficial in high-risk patients, reducing the risk of early relapse.

 

Charlotte Pawlyn, Martin Kaiser, Faith Davies, David Cairns, et al. 

EFFICACY OF QUADRUPLET KCRD (CARFILZOMIB, CYCLOPHOSPHAMIDE, LENALIDOMIDE AND DEXAMETHASONE) INDUCTION FOR NEWLY DIAGNOSED MYELOMA PATIENTS: ANALYSIS OF THE MYELOMA XI STUDY BY MOLECULAR RISK

Conclusion: KCRD is associated with prolonged PFS compared with response-adapted triplet therapy across all molecular risk subgroups, however these are defined. Even with the highly effective quadruplet combination KCRD, UHiR patients continue to have significantly worse outcomes than patients with standard risk disease and there remains an unmet need for novel therapeutic approaches for these patients.

 

Hervé Avet-Loiseau,  Philippe Moreau, Vincent H. J. van der Velden, Michel Attal, et al.

EFFICACY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA BASED ON MINIMAL RESIDUAL DISEASE STATUS: ANALYSIS OF CASSIOPEIA

Conclusion: The addition of DARA to VTd during induction and consolidation deepened responses, as demonstrated by significant increases in MRD-negative rates. Deepened post-consolidation responses with D-VTd led to improved outcomes, with MRD negativity associated with prolonged PFS, versus VTd in patients with NDMM who were transplant eligible.

 

Raymond L. Comenzo, Efstathios Kastritis, Mathew Maurer, Jeffrey Zonder, et al.

SUBCUTANEOUS DARATUMUMAB + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED AMYLOID LIGHT CHAIN (AL) AMYLOIDOSIS: UPDATED SAFETY RUN-IN RESULTS OF ANDROMEDA

Conclusion: DARA-CyBorD provides high overall hematologic response and CR rate in patients with newly diagnosed AL amyloidosis with a well-tolerated safety profile. Enrollment into the randomized portion of ANDROMEDA is ongoing.